Objetivo
Migraine with aura (MA) affects 4% of the global population, causing severe attacks that strongly impact patients’ quality of life.
Currently available treatments are often ineffective, contraindicated or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment. This indicates a large unmet clinical need and a significant commercial potential.
The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system. The device has a unique commercial advantage by combining 1) A high treatment effect, 2) A low risk profile, and 3) Simplicity, compactness and affordability.
To pave the way for regulatory approval, market launch and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.
Ámbito científico
Palabras clave
Programa(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Convocatoria de propuestas
HORIZON-EIC-2023-ACCELERATOR-01
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinador
8000 AARHUS C
Dinamarca
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.